Prognostic Impact of Sarcopenia in Patients with Metastatic Hormone-Sensitive Prostate Cancer.
Ji Hyun LeeByul A JeeJae-Hun KimHoyoung BaeJae Hoon ChungWan SongHyun Hwan SungHwang Gyun JeonByong Chang JeongSeong Il SeoSeong Soo JeonHyun Moo LeeSe Hoon ParkMinyong KangPublished in: Cancers (2021)
The clinical value of sarcopenia has not been determined yet in metastatic hormone-sensitive prostate cancer (mHSPC). We retrospectively evaluated data of 70 consecutive patients with mHSPC receiving treatment with either early docetaxel ( n = 42) or abiraterone acetate ( n = 28) between July 2018 and April 2021. Skeletal muscle index was calculated from cross-sectional areas of skeletal muscle on baseline computed tomography (CT), defining sarcopenia as a skeletal muscle index of ≤52.4 cm 2 /m 2 . Failure-free survival (FFS), radiographic progression-free survival, and time to prostate-specific antigen (PSA) progression were estimated using the Kaplan-Meier method, and differences in survival probability were compared using the log-rank test. Cox proportional hazards regression analysis was conducted to identify the predictors of clinical outcomes. Patients with sarcopenia ( n = 47) had shorter FFS than those without sarcopenia ( n = 23) (median, 20.1 months vs. not reached; log-rank p < 0.001). Sarcopenia was independently associated with shorter FFS (hazard ratio (HR), 6.69; 95% confidence interval (CI), 1.57-28.49; p = 0.010) and time to PSA progression (HR, 12.91; 95% CI, 1.08-153.85; p = 0.043). In conclusion, sarcopenia is an independent prognostic factor for poor FFS and time to PSA progression in patients with mHSPC who receive early docetaxel or abiraterone acetate treatment.
Keyphrases
- skeletal muscle
- prostate cancer
- free survival
- radical prostatectomy
- computed tomography
- insulin resistance
- prognostic factors
- cross sectional
- community dwelling
- small cell lung cancer
- squamous cell carcinoma
- magnetic resonance imaging
- rectal cancer
- adipose tissue
- electronic health record
- magnetic resonance
- locally advanced
- contrast enhanced
- radiation therapy
- artificial intelligence